Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30–50% alive at 5 years. High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consisten...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 366; no. 9492; pp. 1189 - 1196
Main Authors:	Eggermont, Alexander MM, Suciu, Stefan, MacKie, Rona, Ruka, Wlodzimierz, Testori, Alessandro, Kruit, Wim, Punt, Cornelis JA, Delauney, Michelle, Sales, François, Groenewegen, Gerard, Ruiter, Dirk J, Jagiello, Izabella, Stoitchkov, Konstantin, Keilholz, Ulrich, Lienard, Danielle
Format:	Journal Article
Language:	English
Published:	London Elsevier Ltd 01-10-2005 Lancet Elsevier Limited
Subjects:	Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy, Adjuvant Clinical outcomes Combined Modality Therapy Dermatology Drug therapy Female General aspects Humans Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Lymphatic Metastasis Male Medical sciences Melanoma Melanoma - drug therapy Melanoma - pathology Melanoma - secondary Melanoma - surgery Middle Aged Radiology Recombinant Proteins Side effects Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Skin Neoplasms - surgery Survival Toxicity Tumors of the skin and soft tissue. Premalignant lesions Human Alpha interferon Adjuvant treatment Patient Malignant tumor Medicine Clinical stage Surgery Malignant melanoma Randomised controlled trial Observation Clinical trial Dose Comparative study European Organization for Research and Treatment of Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!